U.S. FDA approves GlaxoSmithKline's blood cancer drug


© Reuters.

(Reuters) – The U.S. Food and Drug Administration on Wednesday approved GlaxoSmithKline’s (L:) experimental treatment for a common form of blood cancer.

GSK’s belantamab mafodotin, or BLENREP, was approved for treating adults with relapsed and refractory multiple myeloma who no longer respond to treatment with an immunomodulatory agent, the drugmaker said in a statement.

Multiple myeloma is the second most common form of blood cancer in the U.S. and is generally considered treatable, but not curable.

A U.S. FDA panel had earlier raised safety concerns about the drug causing deposits to gather on the cornea in the eyes, but later voted in its favor saying the benefits of the treatment outweigh the risks.

Approval for belantamab mafodotin, a rival to Johnson & Johnson (N:) and Genmab ‘s (CO:) Darzalex treatment, is seen as important for GSK’s growing oncology portfolio.

Last month, a panel of the European Medicines Agency (EMA) also recommended approving the drug.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

READ  A majority of Scots now believe that climate change is an "immediate and urgent problem"





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here